Novo Nordisk To Enter Phase 3 Development In Alzheimer's Disease With Oral Semaglutide; Decision To Enter Phase 3 Development In Alzheimer's Disease With 14 Mg Oral Semaglutide, A Once-daily Oral Formulation Of Long-acting GLP-1 Analogue Semaglutide